Related Experiment Video
Updated: May 20, 2026
14:49
Conducting Respiratory Oscillometry in an Outpatient Setting
Published on: April 8, 2022
Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study.
Mark D Eisner1, James L Zazzali, Mary K Miller
1Product Development, Inflammation & Respiratory, Genentech Inc. 1 DNA Way, South San Francisco, CA 94080, USA. eisner.mark@gene.com
Summary
Omalizumab therapy improved asthma control in patients with moderate to severe asthma over two years. This real-world study shows sustained benefits for new and established omalizumab users.
Area of Science:
- Pulmonology
- Immunology
- Clinical Practice Research
Background:
- Asthma guidelines highlight the need for adequate asthma control.
- Many patients with moderate to severe asthma do not achieve sufficient control.
Purpose of the Study:
- To evaluate the long-term effects of omalizumab on asthma control.
- This analysis focused on real-world clinical practice settings.
Main Methods:
- An observational cohort study (EXCELS) included omalizumab-treated and non-omalizumab-treated patients (≥12 years) with moderate to severe asthma.
- Asthma control was assessed using the Asthma Control Test (ACT) every six months over two years.
Main Results:
- Over 50% of new omalizumab users achieved clinically meaningful improvement in ACT by six months, with sustained benefits at 24 months.
- Established omalizumab users maintained their asthma control throughout the two-year follow-up period.
- Similar improvements were noted in patients with moderate and severe asthma.
Conclusions:
- Initiating omalizumab therapy leads to clinically relevant and sustained improvements in asthma control over two years.
- Established omalizumab users consistently maintained asthma control during the study period.
More Related Videos
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...